로딩 중…
StockDiggingStockDigging

Certara, Inc.

CERT· NASDAQ
$8.58+5.54%
2026-09-17

Financials

Valuation Metrics

Certara, Inc.'s Market Cap is $1.33B. At end of 2025 it was $1.41B. Ranked #2300 of 3,121 in US market (top 74%), #927 of 1,463 on NASDAQ (top 63%), #143 of 205 in Health Care Equipment & Services (top 70%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.33B
Revenue$408M
Net Income$-68M
Total Assets$1.40B
Net Assets$967M
Employees1,515
Value
P/B1.38x
P/S3.27x
EV/EBITDA17.32x
FCF Yield4.62%
Profitability
ROE-7.08%
ROA-4.89%
Op. Margin1.86%
Revenue Growth0.66%
Earnings Growth-957.07%
Financial Health
Debt Ratio44.83%
Total Debt$292M
FCF$62M
Cash$184M
Current Ratio2.55x
Net Debt/EBITDA1.29x
Dividend
Div. Yield0.00%
Payout Ratio0.00%
Performance
1Y Return-25.46%
1M Return7.12%
From 52W High-38.18%
1Y MDD-67.06%
Trading
Volume2,111,839 shares
Trading Value$18M
Per Share
EPS$-0.44
BPS$6.21

Company Info

CEO Mr. Jon Resnick
Employees 1,515
HQ Radnor, United States

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.